Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease.

Yamamoto S, Suzuki A, Sasaki H, Sekiguchi-Ueda S, Asano S, Shibata M, Hayakawa N, Hashimoto S, Hoshinaga K, Itoh M.

J Bone Miner Metab. 2013 Jan;31(1):116-22. doi: 10.1007/s00774-012-0391-z. Epub 2012 Oct 18.

PMID:
23076292
2.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.

PMID:
17468062
3.

Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.

Olmos JM, Hernández JL, Llorca J, Nan D, Valero C, González-Macías J.

J Clin Endocrinol Metab. 2012 Dec;97(12):4491-7. doi: 10.1210/jc.2012-2999. Epub 2012 Oct 5.

PMID:
23043189
4.

THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.

Xu XJ, Ma DD, Lv F, Wang JY, Liu Y, Xia WB, Jiang Y, Wang O, Xing XP, Yu W, Li M.

Endocr Pract. 2016 Nov;22(11):1267-1276. Epub 2016 Aug 2.

PMID:
27482615
5.

Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.

Borrego Utiel FJ, Bravo Soto JA, Merino Pérez MJ, González Carmelo I, López Jiménez V, García Álvarez T, Acosta Martínez Y, Mazuecos Blanca MA.

Nefrologia. 2015;35(4):363-73. doi: 10.1016/j.nefro.2015.06.018. Epub 2015 Aug 4. English, Spanish.

6.

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.

Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.

PMID:
22968256
7.

Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.

Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM; Fracture Intervention Research Group.

J Bone Miner Res. 2006 Feb;21(2):292-9. Epub 2005 Oct 31.

8.

Kidney transplantation restored uncoupled bone turnover in end-stage renal disease.

Kawarazaki H, Shibagaki Y, Kido R, Nakajima I, Fuchinoue S, Ando K, Fujita T, Fukagawa M, Teraoka S, Fukumoto S.

Clin Nephrol. 2012 Jul;78(1):10-6.

PMID:
22732332
9.

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Ettinger B, San Martin J, Crans G, Pavo I.

J Bone Miner Res. 2004 May;19(5):745-51. Epub 2004 Jan 19.

11.

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.

Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.

J Clin Endocrinol Metab. 2002 Mar;87(3):985-92.

PMID:
11889149
12.

Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.

Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S.

Nephrol Dial Transplant. 2014 Apr;29(4):899-905. doi: 10.1093/ndt/gfu011. Epub 2014 Feb 4.

PMID:
24500308
13.

Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.

Iizuka T, Matsukawa M.

Climacteric. 2008 Aug;11(4):287-95. doi: 10.1080/13697130801959590.

PMID:
18645694
14.

Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation.

Giannini S, D'Angelo A, Carraro G, Antonello A, Di Landro D, Marchini F, Plebani M, Zaninotto M, Rigotti P, Sartori L, Crepaldi G.

Clin Nephrol. 2001 Nov;56(5):353-63.

PMID:
11758005
15.

Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.

Ito H, Ogata H, Yamamoto M, Takahashi K, Shishido K, Takahashi J, Taguchi S, Kinugasa E.

Clin Nephrol. 2009 Jun;71(6):660-8.

PMID:
19473635
16.

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

Trillini M, Cortinovis M, Ruggenenti P, Reyes Loaeza J, Courville K, Ferrer-Siles C, Prandini S, Gaspari F, Cannata A, Villa A, Perna A, Gotti E, Caruso MR, Martinetti D, Remuzzi G, Perico N.

J Am Soc Nephrol. 2015 May;26(5):1205-14. doi: 10.1681/ASN.2013111185. Epub 2014 Sep 5.

17.

Biochemical parameters of bone turnover in kidney transplant recipients.

Smalcelj R, Kusec V, Puretić Z, Mareković Z.

Wien Klin Wochenschr. 1998 May 8;110(9):326-30.

PMID:
9629624
18.

Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.

Sakai A, Ito M, Tomomitsu T, Tsurukami H, Ikeda S, Fukuda F, Mizunuma H, Inoue T, Saito H, Nakamura T; e-ADVANCED Study Group.

Osteoporos Int. 2015 Mar;26(3):1193-202. doi: 10.1007/s00198-014-2991-z. Epub 2015 Jan 16. Erratum in: Osteoporos Int. 2015 Apr;26(4):1453.

19.

Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.

Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, De Peng Y, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L, Santora AC.

Osteoporos Int. 2015 Sep;26(9):2365-74. doi: 10.1007/s00198-015-3141-y. Epub 2015 May 1. Erratum in: Osteoporos Int. 2015 Nov;26(11):2719-20.

Supplemental Content

Support Center